BioSpace News Archive

Increasing applications of human microbiome in healthcare industry, rising incidence of chronic and rare diseases across the globe, and increasing funds for research on microbiome drugs are some key factors expected to drive global Human Microbiome market growth.

Increasing prevalence of various diseases, rapid adoption of holographic techniques in healthcare sector, and rising investments in R&D activities are expected to drive global Medical Holographic Imaging market growth.

Rising prevalence of various retinal disorders, increasing elderly population, and high chances of vision loss due to eye diseases are some key factors expected to drive global Retinal Imaging market growth.

Rising number of surgeries, trauma and burn cases, increasing prevalence of chronic wounds, and high focus on developing advanced products are expected to drive global Wound Cleanser Products market growth.

The global antibody production market size is expected to reach USD 37.81 Billion in 2030 and register a revenue CAGR of 14.4% over the forecast period, according to the latest report by Reports and Data.

The global abdominal aortic aneurysm repair devices market size is expected to reach USD 3.88 Billion in 2030 and register a CAGR of 7.2%, according to the latest report by Reports and Data.

The global kidney function test market size is expected to reach USD 1,440.1 Million in 2030 and register a revenue CAGR of 6.3% over the forecast period, according to a latest report by Reports and Data.

Mosaic Biosciences (“Mosaic” or “the Company”), a protein and antibody discovery company that helps its partners identify next-generation therapies for the prevention and treatment of disease.

The global surgical table market is expected to reach USD 2.54 Billion by 2030, according to a new report by Reports and Data.

Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM (carcinoembryonic antigen-related cell adhesion molecules) antibodies as anti-cancer treatments, today announced that it has signed a collaboration agreement with YUMAB GmbH, a privately-held German biotechnology company.